Are Analysts Expecting A Better 2020 For Apellis Pharmaceuticals Inc (APLS)?

Apellis Pharmaceuticals Inc (APLS) concluded trading on Thursday at a closing price of $68.12, with 2.62 million shares of worth about $178.14 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 181.84% during that period and on Thursday the price saw a gain of about 2.13%. Currently the company’s common shares owned by public are about 110.77M shares, out of which, 96.62M shares are available for trading.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 142 times over the past 12 months. They bought 2,518,724 shares in 62 of the transactions. In 80 selling transactions, insiders dumped 1,839,391 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

However, the stock later moved at a day high price of 68.64, or with a gain of 2.13%. Stock saw a price change of 9.64% in past 5 days and over the past one month there was a price change of -6.00%. Year-to-date (YTD), APLS shares are showing a performance of 13.80% which increased to 23.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.83 but also hit the highest price of $94.75 during that period. The average intraday trading volume for Apellis Pharmaceuticals Inc shares is 2.09 million. The stock is currently trading 3.57% above its 20-day simple moving average (SMA20), while that difference is up 10.09% for SMA50 and it goes to 14.62% higher than SMA200.

Apellis Pharmaceuticals Inc (NASDAQ: APLS) currently have 110.77M outstanding shares and institutions hold larger chunk of about 94.00% of that.

The stock has a current market capitalization of $8.07B and its 3Y-monthly beta is at 0.93. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 3.76 while making debt-to-equity ratio of 1.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLS, volatility over the week remained 4.02% while standing at 4.59% over the month.

Analysts are in expectations that Apellis Pharmaceuticals Inc (APLS) stock would likely to be making an EPS of -$0.71 in the current quarter, while forecast for next quarter EPS is -$0.53 and it is -$1.21 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.09 which is -$0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 26.71% while it is estimated to increase by 72.92% in next year. EPS is likely to grow at an annualized rate of 33.30% for next 5-years, compared to annual growth of -10.80% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on February 05, 2024 offering a Buy rating for the stock and assigned a target price range of between $68 and $80 to it.

Most Popular

Related Posts